Research
Hormonal
Roux-en-Y gastric bypass (RYGB) induces weight loss and metabolic improvements through complex neurohormonal mechanisms (incretins, vagal signaling, microbiome shifts) rather than solely through mechanical restriction or malabsorption.
Surgery works by changing your gut hormones and brain signals, not just by making your stomach smaller. This hormonal shift helps control hunger and blood sugar. Post-surgery, you must follow dietary guidelines to support these new hormonal balances.
GoodQualifiesHIGH confidence
Animal and human studies suggest that the restriction of food reservoir and malabsorption is insufficient to account for RYGB’s effects to enhance satiation and satiety, improve food seeking behaviours and food selection, increase energy expenditure and improve glucose homeostasis.
Why this rating
Supported by multiple animal and human studies, though the exact contribution of each component is still under investigation.
Source
Recent advances in clinical practice challenges and opportunities in the management of obesity
Andrés Acosta et al. · Gut · 2014
DOI 10.1136/gutjnl-2013-306235
narrative_reviewCited 92×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Bariatric surgery (specifically Roux-en-Y gastric bypass) is the only current obesity treatment effective for long-term weight loss and resolution of comorbidities, whereas non-surgical lifestyle and pharmacological interventions typically produce modest, poorly sustained weight loss.Strong
- Newer FDA-approved pharmacological interventions (Lorcaserin, Phentermine-Topiramate ER) produce greater weight loss than older medications but remain less effective than bariatric surgery and carry risks of central nervous system and cardiovascular adverse effects.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →